News Articles for Rohan Hockings

Perth biotech PYC Therapeutics will go to market seeking $653 million to advance four of its treatments through early trial stages and towards their first transaction.

PYC Therapeutics has announced that Peter Coleman has been appointed non-executive chair, effective from the end of its annual general meeting on November 18.

Today's board moves wrap includes Michael Rosenblatt, Jason Haddock, Mark Okeby, Rob Tyson, Oliver Stewart, Charles Mac, David Dikken, Douglas MacLennan, Alexius Chan, Ian Constable, Rohan Hockings, Nick Woolrych, Ronnie Beevor, Gaurav Gupta, Greg Jason, Lisa Breen, Tommy Logtenberg, Paul Berend, Zane Lewis, Joydeep Dasgupta, Brendan Shalders, Anthony Greenaway, Kevin Lynn and Clinton Moxham.

This week's business appointments include Rohan Hockings, Karen Priest, Janelle Marr, and more.

Perth-based biotech company PYC Therapeutics has reappointed Rohan Hockings as its managing director, five days after he announced his resignation.

PYC Therapeutics has ducked into a trading halt, just two days after it was announced that its managing director had resigned.

Perth-based biotech company PYC Therapeutics is on the hunt for a full-time managing director, following the resignation of Dr Rohan Hockings.

Nedlands-based biotech company PYC Therapeutics is rattling the tin for up to $146 million to fund the progression of four novel drug candidates.

Perth biotech company PYC Therapeutics has hit a major milestone in the development of a first-in-class drug to treat a rare eye disease, recently receiving orphan drug designation from the US FDA.

PYC Therapeutics is rattling the tin for up to $74.6 million to fund the progress of its medical drug trials, including for blinding eye and polycystic kidney diseases.

Nedlands-based biotechnology company PYC Therapeutics has raised $30 million to progress its series of drug trials.

Property developer Exal Group has bought a 31,100 square metre lot from a Chinese real estate group, as it progresses its plans for its project worth more than $500 million at the site.

40under40: The journey from an idea to an approved medication is as difficult as putting a person on the moon, Rohan Hockings says.

GenusPlus Group managing director David Riches was named First Amongst Equals at the 2022 40under40 Awards, ahead of a diverse cohort of Western Australia's young business leaders.

The developer is seeking community input before submitting its plans for the vacant site.

A company targeting treatment of blindness was announced as the WA Innovator of the Year on Wednesday night.

Four companies including VeinTech and Vision Pharma have been selected as finalists in the Great for the State category at the Innovator of the Year Awards.

The rising fortunes of biotech company PYC Therapeutics have bolstered the wealth of its major shareholders, most notably chairman Alan Tribe.

Biotech company PYC Therapeutics has sought funding for its lead drug development program that aims to treat childhood blindness.

Our board moves wrap includes Richard Monti, Kristie Young, Bryn Hardcastle, Rohan Hockings, Douglas Huey, Dale Schultz, Paul Summers, and Louie Simens.

Dampier Gold has appointed Gavin Solomon as special advisor to the board of directors.

Phylogica has announced a commercial collaboration with Lions Eye Institute trading under the name Vision Pharma, bringing the biotechnology company a step closer to commercialising its drug delivery technology.

Perth biotech Phylogica today announced positive test results from its drug delivery technology, but the news was not enough to sustain a rally in the company's shares, which have risen 33 per cent over the past week.

Andrew Haslam and Martin Bryant have resigned as non-executive directors of BCI Minerals.

Shares in biomedical technology business Phylogica were up 13 per cent today after the company announced it had completed a $9.1 million recapitalisation.

Phylogica has a new chief executive who is determined to bring the Perth biotech's commercialisation strategy to fruition.

Former IKEA franchise owner Alan Tribe has taken charge at local biotech firm Phylogica, lifting his stake to 20 per cent and becoming chairman on the same day chief executive Stephanie Unwin was replaced by Rohan Hockings.

Malcolm Randall has resigned as chair at MZI Resources, but will remain a non-executive director. Rod Baxter has been appointed chair.